EPZ5676: Potent and Selective DOT1L Inhibitor for MLL Leukemia and Epigenetic Research

Executive Summary: EPZ-5676 is a highly potent and selective inhibitor of the DOT1L histone methyltransferase, displaying an IC50 of 0.8 nM and a Ki of 80 pM under standard biochemical assay conditions (APExBIO). It exhibits >37,000-fold selectivity over related methyltransferases such as CARM1, EZH2, and PRMTs, minimizing off-target effects. EPZ-5676 inhibits H3K79 methylation and downregulates MLL-fusion target genes, eliciting cytotoxicity in MLL-rearranged acute leukemia cell lines (Ishiguro et al., 2025). In vivo, intravenous administration (35–70 mg/kg/day) in nude rat xenograft models achieves complete tumor regression with no significant toxicity. EPZ-5676 is recommended for use in enzyme inhibition and cell proliferation assays, and is a reference tool in epigenetic cancer research (Histone-H2A).

Biological Rationale

DOT1L (Disruptor of telomeric silencing 1-like) is a histone methyltransferase that specifically methylates lysine 79 of histone H3 (H3K79), modulating chromatin structure and transcriptional activation (Ishiguro et al., 2025). In MLL-rearranged leukemia, DOT1L is aberrantly recruited to target genes by MLL fusion proteins, driving sustained H3K79 methylation and oncogenic gene expression. Loss-of-function and chemical inhibition studies confirm that DOT1L activity is essential for the proliferation and survival of MLL-fusion leukemia cells, but less critical for normal hematopoiesis (HDAC4.com). Recent research in multiple myeloma further demonstrates DOT1L dependency for cell viability and highlights its role in regulating immune gene expression and response to therapy (Ishiguro et al., 2025).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 is a SAM-competitive inhibitor that selectively binds to the S-adenosyl methionine (SAM) pocket of DOT1L. This occupation induces a conformational change, exposing a hydrophobic pocket unique to DOT1L and not present in related methyltransferases (APExBIO). By blocking the methyl group donor binding site, EPZ-5676 prevents methyl transfer to H3K79, leading to rapid loss of H3K79 methylation marks in treated cells. The downstream consequence is transcriptional repression of MLL-fusion target genes (e.g., HOXA9, MEIS1), ultimately triggering cell cycle arrest and apoptosis in MLL-rearranged leukemia models (SB-334867.com). In multiple myeloma, DOT1L inhibition also activates interferon-regulated genes and suppresses IRF4-MYC signaling, demonstrating a broader immunomodulatory effect (Ishiguro et al., 2025).

Evidence & Benchmarks

• EPZ-5676 exhibits an IC50 of 0.8 nM and Ki of 80 pM for DOT1L, and is >37,000-fold selective over CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1 (see Table 1, APExBIO).
• In MLL-rearranged leukemia cell lines (e.g., MV4-11), EPZ-5676 inhibits proliferation with an IC50 of 3.5 nM after 4–7 days of treatment (Ishiguro et al., 2025).
• In vivo, nude rats bearing MV4-11 xenografts treated with 35–70 mg/kg/day EPZ-5676 for 21 days showed complete tumor regression without significant toxicity or weight loss (APExBIO).
• DOT1L inhibition upregulates interferon-regulated genes (IRGs), activates DNA sensing pathways (STING1), and enhances the anti-myeloma efficacy of lenalidomide (Ishiguro et al., 2025).
• Genome-scale CRISPR screens confirm that both MLL-rearranged leukemia and multiple myeloma cells are preferentially dependent on DOT1L for survival (Fig. 2, Ishiguro et al., 2025).

Applications, Limits & Misconceptions

Applications:

• Biochemical enzyme inhibition assays targeting DOT1L methyltransferase activity.
• Cell proliferation and cytotoxicity studies in MLL-rearranged leukemia and multiple myeloma models.
• Preclinical evaluation of epigenetic therapies and immunomodulatory drug combinations.

This article extends prior syntheses such as EPZ5676: Potent DOT1L Inhibitor for Precision Leukemia Research by providing updated evidence on immune modulation and combinatorial potential in myeloma, and clarifies translational boundaries compared to DOT1L Inhibitor EPZ-5676: A Mechanistic and Strategic Partner, which focused primarily on leukemia models.

Common Pitfalls or Misconceptions

• EPZ-5676 is not effective in cancers lacking DOT1L or MLL rearrangements; normal cells are largely insensitive at pharmacologically relevant concentrations.
• It does not inhibit methyltransferases outside the DOT1L family at meaningful concentrations (>10 μM), limiting use in broad-spectrum epigenetic screens.
• Solubility in water is negligible; stock solutions must be prepared in DMSO or ethanol (≥28.15 mg/mL in DMSO, ≥50.3 mg/mL in ethanol with ultrasonic assistance).
• Long-term storage of diluted solutions can lead to loss of potency; it is recommended to store DMSO stocks below -20°C and avoid repeated freeze-thaw cycles (APExBIO).
• EPZ-5676 is a research-use-only reagent and has not been approved for clinical human use.

Workflow Integration & Parameters

EPZ-5676 is typically supplied as a solid (molecular weight 562.71). For biochemical assays, dissolve in DMSO to ≥28.15 mg/mL, or in ethanol to ≥50.3 mg/mL with sonication. For cell-based assays, recommended concentrations range from 1–10 nM for sensitive MLL-rearranged lines (e.g., MV4-11), with 4–7 days of treatment to observe cytotoxicity. In vivo, effective dosing in rodent xenograft models is 35–70 mg/kg/day IV for 21 days, as supported by tumor regression data (APExBIO). Solutions should be freshly prepared or stored at -20°C. Avoid prolonged exposure to ambient temperatures. For immunomodulatory studies, combine EPZ-5676 with agents such as lenalidomide to assess synergistic activation of IRGs and suppression of IRF4-MYC signaling (Ishiguro et al., 2025).

For additional guidance on experimental design and epigenetic assay optimization, see Redefining the Translational Epigenetics Frontier, which provides strategic perspectives on integrating DOT1L inhibitors into immuno-oncology workflows. This article updates and refines those recommendations with new combinatorial benchmarks and workflow parameters based on recent peer-reviewed data.

Conclusion & Outlook

EPZ-5676, as offered by APExBIO, represents a state-of-the-art chemical probe for investigating DOT1L-dependent epigenetic regulation in cancer. Its exceptional potency, selectivity, and validated performance in MLL-rearranged leukemia and myeloma models establish it as a reference standard for both enzyme inhibition and cell-based assay systems. Ongoing research continues to expand its utility in dissecting innate immune signaling and combinatorial cancer therapies. However, its specificity and storage constraints require careful experimental planning and interpretation. For further details and ordering information, visit the official DOT1L inhibitor EPZ-5676 (A4166) product page.